STAT+: Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals
WASHINGTON — The Senate is taking pains to avoid another Aduhelm controversy.
In new bipartisan legislation unveiled on Friday, senators included language that would create a “coordinating council” meant to ensure officials across the entire Food and Drug Administration stay in sync when considering medicines under the controversial “accelerated approval” pathway.